000289143 001__ 289143
000289143 005__ 20250415112711.0
000289143 0247_ $$2doi$$a10.1038/s41598-024-57889-z
000289143 0247_ $$2pmid$$apmid:38531926
000289143 037__ $$aDKFZ-2024-00610
000289143 041__ $$aEnglish
000289143 082__ $$a600
000289143 1001_ $$0P:(DE-HGF)0$$aCortés-Ibáñez, Francisco O$$b0$$eFirst author
000289143 245__ $$aCardiac troponin I as predictor for cardiac and other mortality in the German randomized lung cancer screening trial (LUSI).
000289143 260__ $$a[London]$$bMacmillan Publishers Limited, part of Springer Nature$$c2024
000289143 3367_ $$2DRIVER$$aarticle
000289143 3367_ $$2DataCite$$aOutput Types/Journal article
000289143 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711548042_21797
000289143 3367_ $$2BibTeX$$aARTICLE
000289143 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289143 3367_ $$00$$2EndNote$$aJournal Article
000289143 500__ $$a#EA:C020#LA:C020#
000289143 520__ $$aCardiac Troponin I (cTnI) could be used to identify individuals at elevated risk of cardiac death in lung cancer (LC) screening settings. In a population-based, randomized LC screening trial in Germany ('LUSI' study) serum cTnI was measured by high-sensitivity assay in blood samples collected at baseline, and categorized into unquantifiable/low (< 6 ng/L), intermediate (≥ 6-15 ng/L), and elevated (≥ 16 ng/L). Cox proportional-hazard models were used to estimate risk of all-cause and cardiac mortality with cTnI levels. After exclusion criteria, 3653 participants were included for our analyses, of which 82.4% had low, 12.8% intermediate and 4.8% elevated cTnI, respectively. Over a median follow up of 11.87 years a total of 439 deaths occurred, including 67 caused by cardiac events. Within the first 5 years after cTnI measurement, intermediate or elevated cTnI levels showed approximately 1.7 (HR = 1.69 [95% CI 0.57-5.02) and 4.7-fold (HR = 4.66 [1.73-12.50]) increases in risk of cardiac death relative to individuals with unquantifiable/low cTnI, independently of age, sex, smoking and other risk factors. Within this time interval, a risk model based on age, sex, BMI, smoking history and cTnI showed a combined area under the ROC curve (AUC) of 73.6 (58.1-87.3), as compared to 70.4 (53.3-83.5) for a model without cTnI. Over the time interval of > 5-10 years after blood donation, the relative risk associations with cTnI and were weaker. cTnI showed no association with mortality from any other (non-cardiac) cause. Our findings show that cTnI may be of use for identifying individuals at elevated risk specifically of short-term cardiac mortality in the context of LC screening.
000289143 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000289143 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289143 650_7 $$2Other$$aBiomarkers
000289143 650_7 $$2Other$$aLung cancer screening
000289143 650_7 $$2Other$$aMortality
000289143 650_7 $$2Other$$aMyocardial infarction
000289143 650_7 $$2Other$$aRisk assessment
000289143 650_7 $$2Other$$aTroponin
000289143 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron$$b1$$udkfz
000289143 7001_ $$0P:(DE-He78)eba11eff7c9c475da132d5343d569759$$aMascalchi, Mario$$b2
000289143 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b3$$udkfz
000289143 7001_ $$0P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDelorme, Stefan$$b4$$udkfz
000289143 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b5$$eLast author$$udkfz
000289143 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-024-57889-z$$gVol. 14, no. 1, p. 7197$$n1$$p7197$$tScientific reports$$v14$$x2045-2322$$y2024
000289143 8564_ $$uhttps://inrepo02.dkfz.de/record/289143/files/s41598-024-57889-z.pdf
000289143 8564_ $$uhttps://inrepo02.dkfz.de/record/289143/files/s41598-024-57889-z.pdf?subformat=pdfa$$xpdfa
000289143 8767_ $$8SN-2024-00420-b$$92024-05-28$$d2025-04-14$$eAPC$$jZahlung erfolgt
000289143 909CO $$ooai:inrepo02.dkfz.de:289143$$pVDB$$pOpenAPC$$popenCost
000289143 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000289143 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000289143 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)eba11eff7c9c475da132d5343d569759$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000289143 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000289143 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000289143 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000289143 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000289143 9141_ $$y2024
000289143 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2022$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:06Z
000289143 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:06Z
000289143 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:11:06Z
000289143 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-04-12T15:11:06Z
000289143 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-24
000289143 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-24
000289143 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000289143 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000289143 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000289143 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
000289143 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000289143 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000289143 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x1
000289143 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000289143 980__ $$ajournal
000289143 980__ $$aVDB
000289143 980__ $$aI:(DE-He78)C020-20160331
000289143 980__ $$aI:(DE-He78)E010-20160331
000289143 980__ $$aUNRESTRICTED
000289143 980__ $$aAPC